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Introduction
Cancer nanomedicines have the potential to lead to innovative drug formulation strategies through the design of nanocarriers that improve efficacy and bioavailability, incorporate targeting opportunities and may lead to personalization as well as increased safety compared to conventional medicines. [1] [2] [3] Development of successful cancer nanomedicines has been hindered, however, due to the lack of target specificity. 4 Nevertheless, some examples of anti-cancer nanomedicines have reached the clinic. Currently approved treatments include doxorubicin loaded PEGylated liposome formulations (Doxil) for the treatment of ovarian cancer and Karposi's sarcoma 4, 5 and paclitaxel/albumin nanoparticles (Abraxane) for the treatment of metastatic breast cancer 6, 7 . These existing and other emerging 8 nanoformulations are designed to enhance circulation of poorly soluble chemotherapeutics. Other approaches are focused on injecting polymer formulations at the tumor site, to create depots that enable localized drug delivery. 9 As alternatives to lipids or polymers, peptide nanostructures are attractive for biomedical applications 10-13 due to their chemical versatility and the GRAS (generally recognized as safe) status (21CFR72.320) of their amino acid breakdown products.
One example which is currently being assessed for clinical use are peptide nanofiber scaffolds (PuraMatrix) for tissue engineering, drug delivery and regenerative medicine. 14, 15 In the current work, we aim to generate liposome-like peptide nanocarriers able to autonomously form nanofibrous peptide depots at the tumor site in response to enzymes secreted by cancer cells.
Targeting the enzymes that are over-expressed in cancer sites provides a route towards more specific cancer nanocarriers. [16] [17] [18] In particular, a number of enzyme-responsive supramolecular materials have been developed that change their morphology upon enzyme action. [19] [20] [21] [22] [23] [24] Matrix-metalloproteinases (MMPs) are over-expressed in many types of cancer and are involved in metastasis formation due to their ability to degrade the extracellular matrix. 25, 26 Due to this cancer-specific overexpression, the enzymatic activity of MMPs provides opportunities to manage or report cancer progression autonomously and only when and where it is required 20, 21, [27] [28] [29] [30] . MMPs are therefore logical targets for enzyme-triggered therapeutics.
A variety of supramolecular assemblies (such as peptide amphiphiles 21, [31] [32] [33] and polymer-peptide hybrids 34 ) have been developed that dissociate in response to MMP action. Typically, these nanocarrier designs include a hydrophobic core that holds the drug, which is then released in response to the MMP catalyzed breakdown of the carrier. In an alternative approach, enzymatic triggering by cell surface bound enzymes (phosphatases) results in the formation of supramolecular nanofiber networks, providing localized barriers around cancer cells that result in cell death. 22, 35, 36 Enzyme-triggered morphology changes have been used to drive the formation of aggregated, amorphous materials, which selectively accumulate and retain polymer-peptide conjugates in tumor tissues. 20, 37 Recently, a combination therapy consisting of enzyme (carboxylesterase) triggered peptide fibrillization combined with an anticancer drug (cisplatin) was shown to dramatically enhance drug toxicity against drug-resistant cells. 38 The above examples clearly illustrate that supramolecular peptide structures are well-suited to achieve enzyme-triggered morphology transitions. We propose that the peptides may be designed that combine a number of features of the above examples into one system: (1) the peptides should form micelles with hydrophobic cores that can contain doxorubicin; (2) they should be hydrolysable by MMP-9; (3) upon hydrolysis the amphiphilic balance should shift so that nanofibers are formed, which incorporate the doxorubicin (Figure 1) . This would allow for the formation of micelles as mobile nanocarriers, which form localized depots in areas where cancer-specific enzymes are secreted. We designed our system by following design rules for MMP-9 specificity (MEROPS) in combination with the incorporation of short -sheet forming peptides (composed of just four-six amino acids) into the MMP-9 substrate. In this way, hydrophobic pockets (xFFyG, where x is either glycine or phenylacetyl group and y is leucine or alanine) for doxorubicin entrapment and MMP-9 substrates are incorporated in the nanocarrier structure. In order to test whether these systems can indeed perform as autonomously localized release systems (Figure 1) both in vitro and in vivo tests were performed. Ultimately, by using a xenograft mouse model, we
show that localized formation of doxorubicin-containing fibers slows tumor growth compared to treatment with doxorubicin only. Our approach uses a pathological hallmark of metastasis (MMP over-expression) to guide therapeutic targeting, thereby turning a negative prognostic indicator into a therapeutic response.
Materials and Methods

Peptide synthesis
All peptides where synthesized using standard Fmoc solid phase peptide synthesis on Wang resin pre-loaded with the first amino acid. Amino acid coupling was performed with a three-fold excess of the Fmoc protected amino acid over the resin in DMF, using N,N,N ,N -Tetramethyl-O-(1H-benzotriazol-1-yl) uronium hexafluorophosphate (HBTU) and N,N-Diisopropylethylamine (DIPEA) as activating and coupling reagents in 1:2 ratio respectively relative to the amino acid. Fmoc removal was carried out with 20% piperidine in DMF. The cleavage of the peptides from the resin was achieved using a cleavage cocktail: 95% TFA, 2.5 % triisopropylsilane (TIS), and 2.5 % water. The crude peptide was precipitated and washed in cold diethyl ether and subsequently dissolved in water to allow further purification. For the dissolution of hydrophobic sequences minimal amount of acetonitrile was used to ease the dissolution of any non-dissolved material (in water). The samples were then characterised by reverse phase high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LCMS) to determine the purity and Mw of the product. The peptides were purified by Almac Sciences (Elvingston Science Centre, Gladsmuir, East Lothian, Edinburgh, EH33 1EH, Scotland).
Nanostructure formation and characterization
The micelle forming peptide 2a was directly dissolved in deionized water, the pH adjusted to 7.4 and its self-assembly behavior investigated after a cycle of alternating sonication and vortexing. For the expected enzyme cleavage peptide fragment i.e. 2b and the observed cleavage product (2c) the peptide were dissolved in DI water and the pH was increased (NaOH 0.5 M) to solubilize 2b/2c, followed by a slow decrease of pH achieved by addition of HCl 0.5 M, to a final pH of 6.5 -7 to trigger gelation.
Gelation was observed for the expected MMP-9 cleavage product 2b and for the observed cleavage product 2c. Incorporation of doxorubicin was achieved by solubilizing in DMSO by sonication and a 1 mM stock solution in PBS was made and subsequent dilution into a suspension of peptide micelles.
Atomic force microscopy
AFM was performed using a Bruker, NanoScope V, Multimode 8 atomic force microscope. The samples were placed on a trimmed and freshly cleaved mica sheet (G250-2 Mica sheets 1" x 1" x 0.006") attached to an AFM support stub and left to air-dry overnight in a dust-free environment, prior to imaging. All the images were obtained using ScanAsyst in air mode. The resolution of the scans is 512 x 512 pixels.
Typical scanning speed was 1.0 Hz. The images were analysed using NanoScope Analysis software Version 1.50.
Transmission electron microscopy
TEM imaging was performed at the Advanced Science Research Center (ASRC), CUNY Imaging Facility using a FEI, TITAN Halo transmission electron microscope operating at 300kV fitted with CETA 4Kx4K camera. Carbon-coated copper grids (200 mesh) were glow discharged in air for 30 s. 5 l of sample was added to the grid and blotted down using filter paper after 60 s. For double staining, a negative stain (2% aqueous uranyl acetate) was applied twice (30 s each time) and the mixture blotted again using filter paper to remove excess. The dried specimens were then imaged.
Scanning electron microscopy.
SEM imaging was performed at the University of Glasgow Electron Microscopy facility. Cells were allowed to adhere on previously sterilized glass coverslips, serum starved overnight and treated with 100 nM PMA to induce MMP-9 production. Then, they were treated with 2.5 mM of peptide 2a for 72 h. After peptide treatment, the cells were fixed on glass coverslips using 1.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (1 h at 4°C). The cells were then freeze-dried in liquid nitrogen.
Samples were subsequently sputter coated with gold (8 nm thick coating) under vacuum and imaged using a JEOL-JSM 6400 field emission scanning electron microscope operated at an acceleration voltage of 10 kV.
Confocal microscopy
Samples were imaged in a liquid state using a Nikon A1 (Tokyo, Japan), an Olympus 
Western Blot and IHC Analysis
The MMP-9 antibody (EP1255Y, Abcam) was used at a dilution of 1:1,000 for Western blotting of cell culture extracts and 1:200 on fixed organotypic or subcutaneous tumor samples for immunohistochemistry (IHC). For Western blot analysis, cells were lysed using mRIPA buffer (50 mM Tris-HCl, 150 NaCl, 1%
NP-40, 1% sodium deoxycholate, 0.1% SDS and 10 mM EDTA) supplemented with protease inhibitors aprotinin and leupeptin. After SDS-PAGE and transfer to a nitrocellulose membrane (Perkin Elmer), a chemiluminescence detection kit (Amersham) was employed in conjunction with the HRP-linked anti-rabbit IgG antibody (NEB 7074, Cell Signaling) at a 1:10,000 dilution to detect MMP-9 and GAPDH (2118, Cell Signaling) as a loading control. For IHC, standard processing and antigen-retrieval methods were applied using citrate buffer (pH = 6.0) and visualization and enhancement of the secondary biotinylated HRP-linked antibody was achieved by using the ABC Kit (Vectastain) and EnVision TM system (DAKO).
Zymography
Precast 10% zymogram (gelatin) protein gels (Novex TM , ThermoFisher Scientific)
were loaded with 20 L of tissue culture medium, pre-spun at 1200 rpm for 5 min to remove cellular debris. Following SDS-PAGE, gels were renatured and developed in the respective buffers (Novex TM ) and finally developed for 24 hours at 37°C. Gels were then stained with SimplyBlue TM (ThermoFisher Scientific) and scanned.
Cytotoxicity assay
For MTT analysis of proliferation and cytotoxicity of the MMP-9 responsive peptides alone or in conjunction with doxorubicin (doxorubicin hydrochloride was used) on cells, 10 4 of MDA-MB-231-luc-D3H2LN cells were seeded per well in a 96 well plate format and allowed to settle overnight. The following day cells were washed 3 times with PBS and serum starved in serum free medium. They were then treated with 100 nM of PMA overnight and exposed to increasing concentrations of the respective peptides, doxorubicin alone or a combination of 2.5 mM of peptide plus increasing concentrations of doxorubicin for 72 h. Following drug exposure, 5 L of MTT solution (5 mg/mL, Roche) was added per well and incubated to produce formazan for 3-4 hours. Finally 100 L of solubilization buffer (1μ1 isopropanolμDMSO) was added, incubated overnight at 37 °C and the OD at 570 nm determined using a microplate reader (Safire 2, Tecan).
Organotypic Culture Matrices
Organotypic matrices and subsequent invasion assay was performed as described previously. 40 Briefly, 10 5 primary human fibroblasts, between the passages 4-8, were embedded in rat-tail extracted collagen. The detached polymerized mixture was allowed to contract into a malleable 3D matrix for up to 14 days in DMEM supplemented with 10 % FBS and 2 mmol/L L-glutamine. 1 x 10 5 of MDA-MB-231-luc-D3H2LN were seeded on top of the matrices and left to settle for 24 hours. They were then mounted unto a metal grid and an air-liquid-interface created allowing for the invasion process to start. After 3 days the medium below the grid was collected for the MMP-9 activity assay and the cultures fixed in 4% paraformaldehyde, followed by paraffin embedding and processing for haematoxylin and eosin staining. Blank sections were further stained with -MMP9 antibody (EP1255Y, Abcam) for the visualization of MMP-9 expression in and around invading cells.
2.12
In vivo assessment of MMP-9 responsive peptides 2 x 10 6 cells were re-suspended after trypsinisation in 100 L Hank's Balanced Salt Solution (HBSS, Invitrogen) and injected subcutaneously into the flanks of CD1 -/nude mice. Tumors were allowed to develop to a size of 280-400 mm 3 
MMP-9 activity assay
The activity of the MMP-9 was assessed using the SensoLyte ® Plus 520 MMP-9 assay kit (Anaspec, Fremont, CA). Briefly, cell culture supernatants were collected after overnight serum exposure, serum starvation followed by stimulation with 100 nM PMA and 3 day invasion into organotypic matrices and centrifuged for 10 min at 1,000 x g, 4°C. A black 96-well plate covered with MMP-9 antibodies was subsequently used to capture the (pro-)MMP-9 from the sample supernatant. An activation step with APMA (2h) was performed in order to activate pro-MMP-9 and record a total signal of potential MMP-9 activity. After activation the assay substrate (5-FAM/QXL TM 520 FRET) was added and the fluorescence reading performed using a X-Fluor Safire 2 fluorescence plate reader ( ex/ em 4λ0 nm/520 nm). The amount of MMP-9 in each sample was calculated according to the manufacturers instruction on the basis of a standard curve of the catalytic responsive enzyme. The assay was performed in 3 independent experiments for each condition.
Inverted Invasion Assay
Transwell inserts with a pore size of 0.κ m were used as described previously in an inverted invasion assay. 42 To that end, Matrigel (BD) was diluted with PBS to a concentration of 5 mg/mL and allowed to polymerize in the transwell at 37 °C for 30 minutes. 
Results and discussion
MMP-9 triggered micelle to fiber transition for entrapment of doxorubicin
Recent examples demonstrate the integration of enzymatic activity and molecular self-assembly (biocatalytic self-assembly) for the development of cancer therapy. 22, 35, 38 Typically, the molecular design of these structures involve hydrophobic (naphthalene, fluroenyl, lipidic) or polymeric moieties. We aimed to design a system that does not contain new chemical entities, focusing on alpha peptides, because of their inherent biocompatibility and biodegradability through proteolytic digestion to alpha amino acids. Thus, we designed peptide micelles for drug encapsulation, which reconfigure to less mobile fibrillar structures with selective tumor retention due to localized MMP-9 activity (Figure 1a) .
The design of the peptide sequence is based on MMP-9 triggered gelation reported by Xu and co-workers 27 and our previous work on MMP-9 induced micelle-to-fiber transitions of PhAc-FFAGLDD (1a). 43 In addition, a peptidic Peptides 1a/b and 2a/b/c were synthesized and characterized for self-assembly behavior (for HPLC and mass spectroscopy details see Figures S1-S3 ). The characterization of peptide 1a and 1b alongside with the MMP-9 digestion of 1a was previously reported. 43 The enzymatic cleavage of 2a was assessed by treatment with MMP-9 at a concentration of 50 ng/mL, 45, 46 which is in the range of the MMP-9 concentration secreted by cancer cells determined in our experiments (see below). The conversion and product identification were assessed by HPLC and LCMS (Figure S7 and S8). The near-complete enzymatic digestion of GFFLGLDD occurs between 48
to 96 h. Peptide 2a shows conversion to a range of products, the main one being GFFLGL (2c), corresponding to the fragment that is one residue longer than the expected product, as previously observed with 1a 43 , indicating a shift in MMP-9 specificity (Figure 1b) . 47 Other products that formed, but in lower quantities are GFF (+ LGLDD) and (GF) + FLGLDD (Figure S7 and S8) . These results show that there is some residual cleavage by MMP-9 at the F L and F F bonds and is in accordance with previously observed ability of MMP-9 to cleave amyloid peptides. 27, 48, 49 As expected for amphiphilic compounds, AFM and TEM characterization of the precursors revealed spherical aggregates for 2a (Figure 1c and 1d) . In contrast, chemically synthesized positive controls for compounds 2b (Figure S4a ) and 2c
( Figure S5a) , produced fibrillar nanostructures. The morphological change induced by enzymatic cleavage was then monitored by AFM and TEM, confirming that upon enzymatic hydrolysis the micelles reconfigured into fibers, which were similar to those formed by the chemically synthesized cleavage products alone (Figure 1e and Figure S9 ). Thus, peptide 2a is capable of undergoing MMP-9 triggered morphological micelle-to-fiber transition (Figure 1c, 1d, 1e and Figure S 9b) , as reported previously for 1a (also shown in Figure S 9a ). 43 The differential supramolecular organization underpinning this shape change was investigated by infrared (IR) spectroscopy (Figure S4b and S5b) , which suggested the presence of ordered structures. 50 Peptide 2a shows a red shift (broad peak at 1643 cm -1 ) compared to absorption values typical for free peptides in solution (1650-1655 cm -1 ). The 1570-1580 cm -1 absorption band is attributed to the aspartic acid side chain carboxylate group present in 2a. Extended structures are observed for 2b (1630 cm -1 ) showing a complex pattern. 51 -sheet like structures were found for 2c
indicated by the presence of 1625 cm -1 peak (Figure S5b) .
Having established that the peptides were capable of undergoing a morphological change in response to MMP-9 activity, we next investigated whether a therapeutic drug could be encapsulated within the nanostructures. For this purpose, doxorubicin was solubilized in DMSO by sonication and a 1 mM stock solution in PBS was made and subsequently diluted into the suspension of peptide micelles (final concentration of doxorubicin: 5 µM). First, the effect of doxorubicin incorporation on the biocatalytic micelle-to-fiber conversion was investigated. To this end, the starting material (2a) and the observed product of MMP-9 cleavage (2c) were characterized by AFM and TEM in the presence of 0.2% of doxorubicin to assess whether the micelle or fiber formation was disrupted by the presence of the drug. In the presence of doxorubicin, spherical aggregates are still observed for 2a (Figure S6a and S6b) , and fibers for 2c (Figure S6d and S6e) , Doxorubicin fluorescence was also imaged to assess whether the drug was incorporated in the nanostructures. Fluorescence signal (Figure S6c and S6f) from doxorubicin emission is observed in both 2a and 2c, confirming its incorporation in peptide nanostructures. Confocal microscopy ( Figure   S10b ) confirms doxorubicin entrapment in the fibres after enzyme treatment, which is further confirmed by fluorescence studies (Figure S10a) , where a two-stage discontinuous behaviour is shown upon treatment of peptide micelles with MMP-9.
Due to difficulties in separating peptide fragments and DOX, it was not possible to quantitatively determine the DOX loading in the peptide nanostructures.
Treatment with MMP-9 responsive peptides combined with doxorubicin in vitro
Supramolecular peptide based systems have recently been shown to be successful for in vitro and in vivo inhibition of tumor progression based on polymeric nanocarriers (micellar peptide/polymer drug conjugates) 20 or formation of hydrophobic (NapFF), cytotoxic fibres 52 . Our approach differs in that we use peptidic nanocarriers to locally assemble into non-toxic nanostructured depots. To measure the response of the MDA-MB-231-luc-D3H2LN cells to the peptide micelles in vitro, cells had to first be serum starved in order to avoid the effect of non-specific cleavage by MMP-like enzymes contained in serum. 53, 54 They were subsequently stimulated with 100 nM of PMA (Phorbol 12-myristate 13-acetate) in order to express MMP-9, which is secreted by cancer cells to promote 3D invasion 55 (Figure 2a) . Zymograms of the gelatinolytic properties of cell culture supernatants from the cancer cells showed the presence of several MMPs in the serum sample (with bands at around 90 and 70 kDa as expected for MMP-9 and MMP-2 respectively). Serum starved cells treated with PMA, however, only displayed a single degradation band at ~90 kDa, the expected size of MMP-9 (Figure 2b) . Specific MMP-9 cleavage activity was assessed by the use of a fluorimetric ELISA, showing that after PMA stimulation 18.5 ± 4.1 ng/mL of active enzyme could be detected (Figure 2c) .
Biocompatibility of MMP-9 cleavable peptides was then measured in cancer cells by the use of MTT assays. In addition, the non-cleavable D-stereoisomer analogues PhAc-D F D F D AG D LDD (1a(D)) and G D F D F D LG D LDD (2a(D)) were synthesized (Figure S11 and S12) for comparison with the L-stereoisomers. The D-stereoisomers treated with MMP-9 showed no degradation for at least 10 days of treatment (Figure S13 and S14) . MTT assay showed no reduction in viability, while instead a slight increase in proliferation for 1a, 1a(D) and 2a(D) (Figure 2d , > 100 %).
A minor reduction of cell viability for 2a (Figure 2d , 78.3 ± 14.5 %) was observed at concentrations above the critical aggregation concentration of 2.5 mM.
When cells were treated with 2.5 mM of peptide micelles in conjunction with increasing concentrations of doxorubicin, an increased toxicity was observed especially for the MMP-9 cleavable peptides 1a and 2a (Figure 2e-h) . Critically, this behaviour was not observed for the D-stereoisomers of the peptides, 1a(D) and 2a(D), that are not susceptible to MMP-9 digestion (Figure S13 and S14) , therefore the micelle-to-fibre transition does not occur. In Figure 2e -h the observed 60% to 70% of viability in the doxorubicin treated samples is preserved in the combination treatments of D-peptide with doxorubicin. In the case of the L-peptide and doxorubicin combination the cell viability is drastically reduced to 37.5% and 35% for 1a and 2a, respectively.
Up to 5 mM peptide concentrations, both peptide micelle types 1a/2a were found to have minimal effects on cell viability in the absence of doxorubicin (Figure   2d ). However, both peptides showed to increase the effectiveness of doxorubicin over a wide range of concentrations (6.25-500 nM) (Figure 2e and 2f) . In contrast, neither of the non-hydrolysable D-stereoisomers showed this amplification of the effects of doxorubicin treatment. 1a(D) even reduced the effectiveness of doxorubicin treatment, consistent with the idea that doxorubicin could be trapped by peptide micelles, but not released through enzymatic cleavage. Thus, the combination treatment was more toxic to cancer cells compared to doxorubicin alone and also compared to the combination of the D-peptides and doxorubicin, confirming the crucial role of MMP-9 in micelle-mediated drug delivery. These data support a mechanism, whereby the micelle-to-fibre morphology transition results in increased toxicity of the combination treatment due to the formation of fibrillar depots which act to localize the drug near the cancer cells. 
Visualization of peptide nanostructures in vitro
Imaging exogenous peptide nanostructures in the proximity of cells was challenging, mainly because of the lack of intrinsic fluorescence of the peptide assemblies. Signal visualization by confocal microscopy was achieved by co-assembling small percentage (1 %) of fluorescently tagged peptide-conjugates with micelle forming peptides. 56, 57 To this end, peptide 2a was labelled with carboxyfluorescein. Carboxyfluorescein-2a ( ex/em = 492/517 nm) and 2a
co-assemblies were prepared by mixing the two molecules at a ratio of 1/100, followed by sonication. They were imaged using AFM, TEM and fluorescence microscopy (Figure S15) . These results show that the carboxyfluorescein-2a and 2a
co-assemble into spherical aggregates and that carboxyfluorescein is incorporated in the micelles, which made it a good candidate for imaging the distribution of peptides after administration to cells (Figure 3a) .
The imaging of peptides, by laser-scanning confocal microscopy with subsequent deconvolution using an Airyscan unit (Zeiss), in proximity to cancer cells in vitro shows that the peptidic carriers are found in the cytoplasm and nuclei of the cancer cells (pink arrows) with some larger aggregates (orange arrows) also detected outside the cells. The formation of fibrillar nanostructures becomes apparent in the larger aggregates outside of the cell which was further confirmed by SEM (Figure   3b ).
Resolution limitations of confocal microscopy make it difficult to be conclusive on peptide morphology (micelles or fibres) in proximity to cancer cells. However, signal detection is useful for confirmation of the peptides positioning in proximity of cancer cells. Moreover, substantial peptide uptake can be noticed (Figure 3a, 3g) .
Furthermore, the genetic editing and deletion of MMP-9 expression using CRIPSR-Cas9 technology, goes on to demonstrate the need of MMP-9 presence around the cells in order for spherical, micellar aggregates to be efficiently converted into fibrillar network-like nanostructures (see Figure 3c and 3d versus 3g and 3h) . (Figure 4a) .
MMP-9 expression has been demonstrated in primary human breast cancer tumors
samples before by IHC (Immunohistochemistry). 58 Here, the presence of MMP-9 was also visualized by IHC in the developed xenograft tumors and found to be increased at the invasive border of the subcutaneous tumors (Figure 4b) . In order to assess the effect of MMP-9 cleavable peptidic carriers on the delivery and the effect of sub-clinically administered doses of chemotherapeutics, nude mice were allowed to develop primary tumors of a size between 280-400 mm 3 . They were then grouped randomly into treatment groups of 3-4 mice, receiving daily subcutaneous (s.c.)
injections, distal to the primary tumor site, of either the control (1:1 PBS:DMSO), a sub-clinically effective dose of doxorubicin (1 mg/kg) 59, 60 , the respective peptide carrier (36 mg/kg), or a combination of the two. This revealed that the MMP-9 cleavable peptide carriers 1a and 2a augment doxorubicin toxicity when administered in tandem. When compared to the doxorubicin only treatment cohort, the peptide carrier/doxorubicin treatment, especially with 2a, shows to render the tumors in a static progression (Figure 4c and 4e) . Furthermore, the treatment with only 1a had no effect on tumor progression, while 2a seemed to have some delaying effect on tumor growth. This differential effect on tumor growth is in agreement with in vitro results
showing reduced cell growth in the presence of 2a (Figure 2g/h ). On the other hand, the D-peptide versions of both, 1a(D) and 2a(D), as well as their combination with doxorubicin, had no effect on tumor progression (Figure 4d and 4f) . In fact the combination of the D-peptide with the doxorubicin seems to hamper the effect of the chemotherapeutic, compared to when solely doxorubicin was administered, suggesting doxorubicin is not effectively released from the micellar precursors. This demonstrates that MMP-9 cleavable peptide carriers in conjunction with doxorubicin have an increased effect on toxicity toward the developed tumor mass. In addition to the tumor site specific cleavage of the peptide micelles and the local release of the chemotherapeutic, the observed increased toxicity of the combination treatment could be attributed to the possibility of forming reservoirs of doxorubicin at the MMP-9 rich 26 tumor site, with the cleaved peptidic carrier incorporating doxorubicin when forming fibers, as observed in vitro. Indeed here, MMP-9 expression was detected in organotypic matrices, a 3D invasion model, by IHC, after MDA-MB-231-luc-D3H2LN cells had invaded for up to 5 days into the collagen matrix (Figure 5a) . Further, the activity of specifically MMP-9 in the culture medium of the organotypic matrices was measured by fluorimetric ELISA, following three days of invasion of the MDA-MB-231-luc-D3H2LN cells (Figure 5b) . Notably, MMP-9 expression has previously been found to be particularly stimulated when MDA-MB-231 cells came in contact with extracellular matrix components and especially matrigel in vitro, potentially aiding invasion. 62 Due to the fact that we observed increased MMP-9 expression at the invasive edge of the subcutaneous tumors (see Figure 4b) , we wanted to assess whether the peptides themselves had any effect on the invasion of cells. In order to assess the effect on invasion of the MMP-9 cleavable peptidic carriers alone, MDA-MB-231-luc-D3H2LN cells were allowed to invade in an inverse invasion assay, containing matrigel, for up to 5 days (Figure 5c ). 42 Cells exposed to 2.5 mM of either peptide 1a or 2a showed a significant reduction in their invasion (Figure 5d ). Scanning Electron Microscopy (SEM) further showed an alteration in the lamellipodia formation of the cells stimulated with PMA and treated with the L-peptide 2a, but not the D-peptide 2a, indicating possible hindrance of migration ( Figure S16) . Further, the quantification of circulating tumor cells (CTCs) in the blood of the xenograft mice was performed. CTCs have an important role as markers of tumor progression and as such could be applied to reveal drug resistance in real time. 64 Here, we observed a rescue effect of combination treatment of doxorubicin and 2a compared to the elevated number of CTCs measured for doxorubicin treatment alone (Figure S17) . Having shown that MMP-9 expression is particularly prominent at the tumor border of xenograft subcutaneous MDA-MB-231-luc-D3H2LN tumors, the treatment with these peptidic carriers could localize drug delivery and retentions at these crucial sites of tumor progression. The additional effect of the treatment with the peptides alone hindering invasion in a 3D in vitro assay could be another benefit of treating the primary tumor with the peptidic carrier, potentially hampering metastatic dissemination.
Conclusions
In summary, peptides may act as 'safe' and highly tuneable building blocks of nanostructures, which are attractive due to low toxicity of their degradation products.
Therefore, peptides and polymer-peptide conjugates gained attention in the last two decades as designable alternatives to liposomal nanostructures that have reached the clinic as doxorubicin vehicles for cancer treatment (example Doxil). More recently, nanoscale peptide vectors used for physical encapsulation of anticancer drugs were able to show better performance compared to the drugs only. 38, 65, 66 Here, two different MMP-9 responsive peptide amphiphiles able to self-assemble into spherical 
